Detalhe da pesquisa
1.
Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
Platelets
; 34(1): 2195016, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37013676
2.
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Br J Haematol
; 197(3): 359-366, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179784
3.
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study.
Ther Adv Hematol
; 14: 20406207231179856, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37465395
4.
Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Adv Ther
; 38(6): 3113-3128, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934279
5.
Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease.
Clinicoecon Outcomes Res
; 12: 515-526, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32982341
6.
Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures.
J Med Econ
; 21(8): 827-834, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912593
7.
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia.
Res Pract Thromb Haemost
; 7(3): 100134, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37193124
8.
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Invest New Drugs
; 25(2): 115-22, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17072745